Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
Status:
Completed
Trial end date:
2014-04-14
Target enrollment:
Participant gender:
Summary
The purpose of this randomized phase II trial is to determine the clinical feasibility - in
terms of patients without dose limiting toxicities or premature treatment withdrawal or death
- of the combination of Cisplatin and Pemetrexed and of the combination of Cisplatin and
Vinorelbine. The combination of Cisplatin / Pemetrexed is assumed to be distinctly less toxic
than Vinorelbine / Cisplatin.
Phase:
Phase 2
Details
Lead Sponsor:
Thoraxklinik am Universitätsklinikum Heidelberg Thoraxklinik-Heidelberg gGmbH